Shattuck Labs, Inc. (STTK) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Current obligations | 7.73M USD | Liabilities, Current |
| Cash and equivalents | 63.30M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $7.73M | $63.30M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $4.25M | $90.42M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $7.05M | $54.19M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $5.34M | $42.55M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $5.34M | $50.47M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $7.32M | $60.90M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $8.92M | $57.39M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $12.40M | $43.83M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $15.03M | $60.69M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $14.33M | $76.00M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $11.45M | $125.63M | $5.00M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $14.06M | $40.63M | $60.44M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $12.99M | $71.89M | $45.28M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $16.01M | $66.04M | $69.45M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $24.96M | $47.38M | $113.90M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $19.14M | $39.76M | $145.36M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $24.25M | $37.87M | $176.37M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $16.81M | $50.74M | $188.48M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $24.59M | $92.27M | $176.54M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $19.84M | $85.09M | $205.12M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $15.11M | $86.49M | $218.30M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $17.90M | $84.73M | $236.44M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $16.83M | $157.90M | $177.55M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $16.48M | $128.60M | $6.34M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $19.98M | $7.01M | $32.07M | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |